ClinicalTrials.gg
CompletedNCT02561065TANSNIP-PESAUpdated Apr 28, 2021

Long-term Impact Evaluation of a Worksite-based Lifestyle Intervention to Reduce Cardiovascular Risk in Office Workers

An interventional study of Lifestyle intervention in Atherosclerosis, sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III. Completed. Open to participants aged 40 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-28.

Sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,020
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
All
01

Study summary

The main objective of TANSNIP-PESA is to determine in a population of asymptomatic bank employees with high and low imaging defined cardiovascular disease (CVD) risk the effectiveness of a comprehensive 3-year worksite-based lifestyle intervention consisting of 12 personalized lifestyle counseling sessions, a Fitbit physical activity tracker and a sit-stand Workstation.

Read the detailed description

We will study the effectiveness of a 30-month worksite-based lifestyle program aimed to promote cardiovascular health in participants having a high or a low degree of subclinical atherosclerotic plaque burden (SAPB), compared to standard care.

Methods: We will conduct a randomized controlled trial (RCT) including middle-aged bank employees from the ´Progression of Early Subclinical Atherosclerosis´ (PESA) cohort, stratified by SAPB. Within each stratum, participants will be randomized 1:1 to receive a lifestyle program or standard care.

The primary outcome measure is the adapted FUSTER-BEWAT CVD risk and lifestyle composite score and secondary outcome measures include physical activity, sedentary time, standing time, diet, smoking, anthropometric measures, blood biomarkers, self-rated health, work-related outcomes, healthcare consumption, program process measures and cost measures.

02

Conditions studied

  • Atherosclerosis

Keywords

  • Health Lifestyle
  • Lifestyle Risk Reduction
  • Health Behavior
  • Sedentary Lifestyle
  • Intervention Studies
  • Cardiovascular risk in office workers
  • Motivational Interview
  • Preventive health services
  • Health education
  • Physical activity
  • Dietary behaviour intervention
  • Workplace
03

In context

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

This study's enrollment of 1,020 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.

Browse Atherosclerosis studies →

Lead sponsor

Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Employees aged 40 to 60 years of the PESA (Progression of Early Subclinical Atherosclerosis) cohort study (48) from the Banco de Santander Headquarters in Madrid (Spain).
  2. Employees to be included need to be 1 year before PESA 2/3 visit (-1/ +2 months deviation).
  3. Employees that can be stratified into a high or low degree of imaging defined SAPB. High degree of imaging-defined SAPB will be defined as a high burden of atherosclerotic disease detected either by 2D ultrasound (upper tertile sum of maximum thickness of the plaques or coronary artery calcium score (CACS) by computed tomography ≥ 1 point). Low degree of imaging-defined SAPB will be defined as having a CACS Agatston score of zero and no plaque by 2D ultrasound or being in the lowest two tertiles of plaque burden. Participants without plaque burden but with a ≥ 25, or; reporting at least one unhealthy lifestyle behavior in their last PESA visit (i.e., \<150 min/wk of at least moderate intensity physical activity assessed by accelerometer, sitting >7 h/d as assessed by accelerometer, not meeting Mediterranean diet guidelines as assessed by a computerized dietary history tool previously developed and validated in the EPIC-Spain study and improved by ENRICA investigators, or smoking) will also be included in the low SAPB group.

Exclusion criteria

Exclusion Criteria:

  1. Prior history of cardiovascular disease (myocardial infarction, angina pectoris, stroke, peripheral vascular disease, aortic aneurysm, angioplasty, heart surgery, atrial fibrillation, or any other heart disease).
  2. Active treatment for cancer, history of transplant with active or immunomodulator treatment.
  3. Morbid obesity ( ≥40 kg/m2).
  4. Presence of any disease that decreases to 3 years, or any condition that could affect adherence to the study procedures.
  5. Participants are also excluded if they are pregnant or lactating women.
  6. Employees without plaque burden, a healthy BMI and a healthy lifestyle will be excluded from the RCT.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,020 participants (actual)

Study arms

  • Experimental
    Lifestyle intervention high risk group.

    Participants in the intervention group will receive the intervention on top of standard care.

    Behavioral: Lifestyle intervention

  • No intervention
    Standard care high risk group.

    Each participant in the standard care group will receive care as usual, provided by his own occupational physician (OP) and other possible care providers.

  • Experimental
    Lifestyle intervention low risk group.

    Participants in the intervention group will receive the intervention on top of standard care.

    Behavioral: Lifestyle intervention

  • No intervention
    Standard care low risk group.

    Each participant in the standard care group will receive care as usual, provided by his own occupational physician (OP) and other possible care providers.

Interventions

  • BehavioralLifestyle intervention

    1. Each participant will receive 12 personalized lifestyle counseling sessions given face-to-face by a trained practitioner. 2. The Fitbit physical activity tracker gives summaries of the participant's physical activity, provides stimulating prompts and rewards, and allows for social media sharing and competition. 3. A Sit-stand workstation allows to adjust the height of the participant workstation, including the computer screen, keyboard and mouse and allows them to easily switch between sitting and standing throughout the workday.

06

What researchers measure

Primary outcomes

  1. Adapted FUSTER-BEWAT score (Blood pressure, Physical activity, Sedentary time, Body Mass Index, Fruit and Vegetable Consumption and Smoking).

    Composite score consisting of: Blood pressure, Physical activity, Sedentary time, Body Mass Index, Fruit and Vegetable Consumption (as a proxy for overall diet) and Smoking.

    Time frame: Changes between baseline, and Year 1, and Year 2 and Year 3.

Secondary outcomes

  1. Original FUSTER-BEWAT score.

    The initial FUSTER-BEWAT score will also be calculated in addition as a secondary outcome for future testing of psychometric properties of the adapted FUSTER-BEWAT score

    Time frame: Changes between baseline, and Year 1, and Year 2 and Year 3.

  2. Objective physical activity/sedentary time.

    Physical activity and sedentary time will be objectively assessed with an activPAL activity monitor (PAL technologies Limited, Glasgow, UK). Participants will also complete a short daily diary, reporting the exact wearing times.

    Time frame: Changes between baseline, and Year 1, and Year 2 and Year 3

  3. Self-reported lifestyle behaviors.

    The following questionnaires regarding physical activity and sedentary behavior will be administered: the International Physical Activity Questionnaire (IPAQ short form) (also at 4 and 6 months); the Occupational Sitting and Physical Activity Questionnaire (OSPAQ) (also at 4 and 6 months); the Workforce Sitting Questionnaire (WSQ) (also at 4 and 6 months); and single questions to assess average daily standing. Data on dietary habits will be collected (also at 4 months) with the Mediterranean Diet Adherence Screener (MEDAS). Smoking status will be a self-reported measure, as well as the average number of cigarettes or other tobacco products consumed daily. Further, sleeping will be measured using the Sleep Habits Questionnaire developed by the Sleep Heart Health Study.

    Time frame: Changes between baseline, and Year 1, and Year 2 and Year 3

  4. Physical assessments.

    Waist circumference, body height, body weight, and blood pressure.

    Time frame: Changes between baseline, and Year 1, and Year 2 and Year 3.

  5. Cardio-metabolic biomarkers.

    Complete blood count and chemistry panel as well as specific biomarkers related to subclinical atherosclerosis will be obtained.

    Time frame: Changes between baseline, and Year 1, and Year 2 and Year 3.

  6. Psychosocial assessment.

    Depression will be measured using the Center for Epidemiologic Studies Depression Scale (CES-D). Perceived stress will be measured using the Perceived Stress Scale (PSS). Social support will be measured using the official Spanish translated ENRICHD Social Support Instrument (ESSI). Job strain will be measured with an adapted version of the official Spanish translation of the Job Content Questionnaire (JCQ). Quality of life will be self-reported using the EuroQol (EQ-5D-5L). Relaxation and detachment after work will be measured using the Recovery Experience Questionnaire. Self-rated health will be assessed with the EuroQol Visual Analogue Scale (EQ VAS). Vitality will be measured using the Vitality questionnaire (VITA-16).

    Time frame: Changes between baseline, and Year 1, and Year 2 and Year 3.

  7. Personal characteristics.

    Sociodemographic information, including age, gender, marital status, working hours per week, employment status, job type, income and education level, will be assessed.

    Time frame: Changes between baseline, and Year 1, and Year 2 and Year 3.

  8. Economic evaluation.

    To evaluate the cost-effectiveness of the lifestyle program, sickness absenteeism, presenteeism (i.e., working while feeling ill) and healthcare consumption (e.g. general practitioner, allied health professionals, complementary medicine consumption) will be assessed every 3 months until 36 months after baseline. Sickness absenteeism and presenteeism will be assessed with items from the WHO Health and Work Performance Questionnaire (WHO-HPQ). Presenteeism is conceptualized in the WHO-HPQ as a measure of actual work performance in relation to best performance, irrespective of the presence or absence of health complaints. Sickness absenteeism will be self-reported using the WHO-HPQ in hours per month.

    Time frame: Changes between 4 months up to 36 months (every 3 months measured).

  9. Intervention process measures.

    Feasibility of the program using quantitative and qualitative methods on three levels: the participant, the psychologist and the stakeholder.

    Time frame: Changes between baseline, 4 months and Year 1, and Year 2 and Year 3

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Garcia-Lunar I, van der Ploeg HP, Fernandez Alvira JM, van Nassau F, Castellano Vazquez JM, van der Beek AJ, Rossello X, Fernandez-Ortiz A, Coffeng J, van Dongen JM, Mendiguren JM, Ibanez B, van Mechelen W, Fuster V. Effects of a comprehensive lifestyle intervention on cardiovascular health: the TANSNIP-PESA trial. Eur Heart J. 2022 Oct 11;43(38):3732-3745. doi: 10.1093/eurheartj/ehac378. PubMed 35869885 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Jan 2020, 56 months.

Of 178 non-industry interventional studies with no phase under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 56 months is above that.

Counting every sponsor, half of 198 studies reached it within 30 months; a quarter within 17 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2015
First posted
Sep 25, 2015
StartActual
May 25, 2015
Primary completionActual
Jan 30, 2020
CompletionActual
Jan 30, 2020
Last update
Apr 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02561065
Lead sponsor
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Collaborators
Amsterdam UMC, location VUmc, Instituto de Salud Carlos III, Icahn School of Medicine at Mount Sinai
Responsible party
Sponsor
First posted
Sep 25, 2015
Start date
May 25, 2015
Primary completion
Jan 30, 2020
Completion
Jan 30, 2020
Last update
Apr 28, 2021

Study contacts

Valentin Fuster, MD, PhD
study chair · Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Jose Maria Castellano, MD, PhD
principal investigator · Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Hidde van der Ploeg, PhD
principal investigator · Amsterdam UMC, location VUmc
Willem van Mechelen, MD, PhD
principal investigator · Amsterdam UMC, location VUmc
Borja Ibañez, MD, PhD
principal investigator · Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)
Antonio Fernandez-Ortiz, MD, PhD
principal investigator · Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)
Ines García Lunar, MD, PhD
principal investigator · Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion